Growing evidence has led to an event that the adhesion G protein‐coupled receptor G6 (ADGRG6) enhancer mutations are high‐frequency among bladder cancer patients after TERT.29, 30. This evidence concerns the gene ADGRG6 and urinary bladder carcinoma.